Diamyd Medical AB (fra:DMN) Share Price

Company Profile

Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWE
T: +46 86610026
https://www.diamyd.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2027
Employees
45

Recommended

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.

Jacob Robbins | 21 September 2026

Morningstar analysts’ take on the takeover for this undervalued industrial player.

Esther Holloway | 20 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,919.10	3.60	-0.04%
CAC 40	8,143.49	78.47	0.97%
DAX 40	25,605.62	301.56	1.19%
Dow JONES (US)	52,006.48	323.84	0.63%
FTSE 100	10,766.29	107.16	1.01%
HKSE	25,042.71	291.93	1.18%
NASDAQ	26,522.54	104.25	0.39%
Nikkei 225	65,018.95	882.70	1.38%
NZX 50 Index	13,821.20	82.06	0.60%
S&P 500	7,696.18	45.68	0.60%
S&P/ASX 200	8,731.90	0.70	0.01%
SSE Composite Index	3,949.91	38.04	0.97%